IRB #

STUDY00020946

Title

A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

Principal Investigator

Christopher Ryan

Study Purpose

This study is being done to test the good and bad effects of DCC-3014-01-001 in patients with Diffuse Tenosynovial Giant Cell Tumor (DTGCT).

Medical Condition(s)

Diffuse Tenosynovial Giant Cell Tumor (DTGCT), pigmented villonodular synovitis, giant cell tumor of the tendon sheath

Eligibility Criteria

1. Men and women 18 years or older
2. Have histologically confirmed diagnosis of DTGCT (formerly known as pigmented villonodular synovitis or giant
cell tumor of the tendon sheath).
3. Adequate organ function
4. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. Participants will be followed for up to 2 years after last study drug dose.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Deciphera Pharmaceuticals, LLC

Recruitment End

01/01/2022

Compensation Provided

No


Go Back